A Phase 3 interventional study of ceftobiprole medocaril and vancomycin+aztreonam in Acute Bacterial Skin and Skin Structure Infections, sponsored by Basilea Pharmaceutica. Completed at 34 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Basilea Pharmaceutica · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients with ABSSSIs. Randomization was stratified by study site and type of ABSSSI (with major cutaneous abscess comprising ≤ 30% of the Intent-to-Treat [ITT] population).
Primary endpoint for FDA: Early clinical response based on the percent reduction in lesion size at 48-72 hours compared to baseline in patients who did not receive rescue therapy and were alive, in the ITT population.
Primary endpoint for EMA: Investigator-assessed clinical success at the test-of-cure (TOC) visit 15-22 days after randomization, in the co-primary ITT and Clinically Evaluable (CE) populations.
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of ABSSSI, meeting at least one of the definitions in (a) to (c) below. Local symptoms must have started within the 7 days prior to the Screening visit:
Cellulitis/erysipelas, defined as a diffuse skin infection characterized by all of the following within 24 hours:
iii. At least two of the following local signs of infection:
Major cutaneous abscess, defined as infection characterized by a collection of pus within the dermis or deeper that is apparent upon visual examination before or after therapeutic intervention and is accompanied by all of the following within 24 hours:
ii. At least two of the following local signs of infection:
Wound infection, defined as infection of any apparent break in the skin characterized by at least one of the following:
i. Superficial incision/surgical site infection meeting all of the following criteria:
ii. Post-traumatic wound (including penetrating trauma, e.g., needle, nail, knife, insect and spider bites) meeting the following criterion within 24 hours:
At least one of the following regional or systemic signs of infection at the Screening visit:
EXCLUSION CRITERIA
Patients meeting any one of the following:
Use of any systemic antibacterial treatment within 14 days, or topical antibacterial administration on the primary lesion within 96 hours, before first infusion of study drug.
Exception: Receipt of a single dose of a short acting (half-life ≤ 12 hours) antibacterial therapy (e.g., for surgical prophylaxis) within > 3 days before randomization (i.e., patients cannot have received any antibacterial treatment within 72 hours of randomization).
The primary ABSSSI is due to, or associated with, any of the following:
Women who are of and unwilling to use an acceptable method of during the study: female sterilization (bilateral tubal occlusion or oophorectomy, or hysterectomy) or male partner vasectomy; intrauterine device (IUD); combined (estrogen and progesterone containing) hormonal contraception (oral, vaginal ring, or transdermal patch) with an ethinylestradiol dose of at least 30 µg, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm or a cervical cap; or total sexual abstinence.
Women are not considered to be of childbearing potential if they are either ≥ 1 year (where menopause is defined as at least 12 months of amenorrhea), or have a serum follicle stimulating hormone (FSH) measurement consistent with post-menopausal status according to local laboratory thresholds. An FSH measurement at Screening is to be obtained for post-menopausal females aged \< 50 years, or for those aged ≥ 50 years who have been post-menopausal for \< 2 years.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
Drug: ceftobiprole medocaril
Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
Drug: vancomycin+aztreonam
ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
Also known as: ceftobiprole
Drug pages: Vancomycin · Aztreonam
Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor. Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.
Early Clinical Response
Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population
Time frame: 48-72 hours after start of study drug treatment
Investigator-assessed Clinical Success in the ITT Population
Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population
Time frame: 15-22 days after randomization
Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population
Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population
Time frame: 15-22 days after randomization
Patients with an ABSSSI who received any systemic antibacterial treatment within 14 days, or topical antibacterial administration on the primary lesion within 96 hours, before first infusion of study drug were not allowed to enter the study. Hospitalization in a medical clinic was mandatory for the first 72 hours.
| Milestone | Ceftobiprole Medocaril | Vancomycin+Aztreonam |
|---|---|---|
| Started | 335 | 344 |
| Completed | 309 | 308 |
| Not completed | 26 | 36 |
| Withdrew: Withdrawal by subject | 8 | 13 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 13 | 18 |
| Withdrew: Other reasons | 3 | 2 |
Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population
| Participants | Ceftobiprole Medocaril | Vancomycin+Aztreonam |
|---|---|---|
| Early Clinical Response | 306 | 303 |
Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population
| Participants | Ceftobiprole Medocaril | Vancomycin+Aztreonam |
|---|---|---|
| Investigator-assessed Clinical Success in the ITT Population | 302 | 306 |
Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population
| Participants | Ceftobiprole Medocaril | Vancomycin+Aztreonam |
|---|---|---|
| Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population | 277 | 279 |
Collected over Up to 35 days after last treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ceftobiprole Medocaril | 1/334 (0.3%) | 6/334 (1.8%) | 63/334 (18.9%) |
| Vancomycin+Aztreonam | 3/342 (0.9%) | 12/342 (3.5%) | 47/342 (13.7%) |
| Event | Ceftobiprole Medocaril | Vancomycin+Aztreonam |
|---|---|---|
| SKIN BACTERIAL INFECTIONINFECTIONS AND INFESTATIONS | 1/334 | 3/342 |
| CELLULITISINFECTIONS AND INFESTATIONS | 0/334 | 2/342 |
| PNEUMONIAINFECTIONS AND INFESTATIONS | 1/334 | 0/342 |
| ACCIDENTAL OVERDOSEINJURY, POISONING AND PROCEDURAL COMPLICATIONS | 1/334 | 0/342 |
| BRONCHIAL OBSTRUCTIONRESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | 1/334 | 0/342 |
| PRURITUSSKIN AND SUBCUTANEOUS TISSUE DISORDERS | 1/334 | 0/342 |
| RASHSKIN AND SUBCUTANEOUS TISSUE DISORDERS | 1/334 | 0/342 |
| DEEP VEIN THROMBOSISVASCULAR DISORDERS | 1/334 | 1/342 |
| CARDIAC ARRESTCARDIAC DISORDERS | 0/334 | 1/342 |
| ABDOMINAL PAINGASTROINTESTINAL DISORDERS | 0/334 | 1/342 |
| Event | Ceftobiprole Medocaril | Vancomycin+Aztreonam |
|---|---|---|
| NauseaGastrointestinal disorders | 36/334 | 20/342 |
| HeadacheNervous system disorders | 19/334 | 24/342 |
| DiarrhoeaGastrointestinal disorders | 21/334 | 16/342 |
ITT population
| Age, Categorical(Participants) | Ceftobiprole Medocaril | Vancomycin+Aztreonam | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 294 | 292 | 586 |
| >=65 years | 41 | 52 | 93 |
| Sex: Female, Male(Participants) | Ceftobiprole Medocaril | Vancomycin+Aztreonam | Total |
|---|---|---|---|
| Female | 137 | 143 | 280 |
| Male | 198 | 201 | 399 |
| Race/Ethnicity, Customized(Participants) | Ceftobiprole Medocaril | Vancomycin+Aztreonam | Total |
|---|---|---|---|
| White | 318 | 330 | 648 |
| Black or African American | 7 | 8 | 15 |
| Asian | 0 | 1 | 1 |
| American Indian or Alaska Native | 4 | 3 | 7 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Other | 5 | 2 | 7 |
| Hispanic or Latino | 103 | 115 | 218 |
| Region of Enrollment(participants) | Ceftobiprole Medocaril | Vancomycin+Aztreonam | Total |
|---|---|---|---|
| Hungary | 2 | 1 | 3 |
| United States | 203 | 215 | 418 |
| Ukraine | 82 | 80 | 162 |
| Bulgaria | 48 | 48 | 96 |
| Type of ABSSSI(Participants) | Ceftobiprole Medocaril | Vancomycin+Aztreonam | Total |
|---|---|---|---|
| Cellulitis/erysipelas | 112 | 111 | 223 |
| Major cutaneous abscess | 96 | 93 | 189 |
| Wound infection | 127 | 140 | 267 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Apr 2019, 14 months.
Results were first posted in May 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceftobiprole medocaril